Chronic News and Research

RSS

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

IOVS journal publishes first global consensus report on MGD

The first global consensus report on meibomian gland dysfunction - a major cause of lid disease and evaporative dry eye - has been published in a special issue of the Investigative Ophthalmology & Visual Science journal.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

New discovery on IL-23 can lead to novel IBD treatments

A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Positive results from Intercept OCA Phase II trial in patients with PBC

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

ACAAI to launch 15th annual Nationwide Asthma Screening Program

The nation's allergists help adults and children learn if they are at risk for asthma or exercise-induced bronchoconstriction as the American College of Allergy, Asthma and Immunology conducts its 15th annual Nationwide Asthma Screening Program.

31 Mar 2011

Study finds frequent anaemia in patients with chronic respiratory failure

A study of nearly 600 patients with severe non-inflammatory respiratory disease has found that a significant percentage also suffered from anaemia, according to the April issue of IJCP, the International Journal of Clinical Practice.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Master regulators of cholesterol and fat play key role in liver fibrosis development

UCLA researchers have demonstrated that a key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis - the build-up of collagen scar tissue that can develop into cirrhosis. Cirrhosis, in turn, is a major cause of premature death and is incurable without a liver transplant.

31 Mar 2011

Thirty four new beneficial compounds found in pure maple syrup

University of Rhode Island researcher Navindra Seeram has discovered 34 new beneficial compounds in pure maple syrup and confirmed that 20 compounds discovered last year in preliminary research play a key role in human health.

31 Mar 2011

Chronic News and Research

New study examines psychological, social challenges of women with breast cancer

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

IOVS journal publishes first global consensus report on MGD

New data confirms antiviral activity of fluvastatin in patients with HCV

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

New discovery on IL-23 can lead to novel IBD treatments

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

New signaling pathway discovery sheds light on chronic dermatitis

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Positive results from Intercept OCA Phase II trial in patients with PBC

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

ACAAI to launch 15th annual Nationwide Asthma Screening Program

Study finds frequent anaemia in patients with chronic respiratory failure

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Master regulators of cholesterol and fat play key role in liver fibrosis development

Thirty four new beneficial compounds found in pure maple syrup

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News